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Summary Decay-accelerating-factor (DAF, CD55), a phosphatidyl-inositol anchored glycoprotein, is a
member of the cell membrane bound complement regulatory proteins that inhibit autologous complement
cascade activation. DAF was found expressed on cells that are in close contact with serum complement
proteins, but also on cells outside the vascular space and on tumour cells. Using CD55(BRIC110) and
CD55(143-30) we show here that DAF(CD55) is only sporadically expressed on the luminal surface of normal
colonic epithelium. However, 5/20 adenomas expressed DAF(CD55) on the cell surface of all tumour cells,
5/20 adenomas were completely negative, 10/20 adenomas expressed DAF(CD55) in various amounts.
DAF(CD55) was expressed in various intensities on almost all tumour cells of the colon carcinoma cell line
HT29. In 5/88 colorectal carcinomas DAF(CD55) was localised on the apical cell surface of all tumour cells,
31/88 were completely negative, 52/88 expressed DAF(CD55) in parts of their neoplastic populations. There
was no correlation between the tumour grading, staging and location and the mode of DAF(CD55) expres-
sion, but DAF(CD55) was found more often in mucinous carcinomas (P= 0.007).
Although the mode of DAF(CD55) expression is not correlated with tumour prognostic parameters, the
upregulation of DAF(CD55) in a subset of adenomas and carcinomas needs further investigation concerning
protection of tumour cells against complement cytotoxity.
During the complement cascade activation complement
fragments can be deposited on autologous cells that are not
the desired target (Davitz et al., 1986). In order to avoid the
destruction of cells by complement, there are several mem-
brane bound regulatory proteins that inhibit the complement
cascade activation (Kinoshita, 1991). One regulatory protein
of the C3/C5 convertase is the 'decay accelerating factor'
(DAF) (Lublin & Atkinson, 1989). DAF is a phosphatidyl-
inositol anchored cell membrane protein (Low, 1987) with a
Mr of 70 kDa on erythrocyte membranes (Nicholson-Weller
et al., 1982). The DAF gene is located in the complement-
regulatory locus on the long arm of chromosome 1 (Lublin et
al., 1987). DAF blocks the C3 and C5 convertases of the
classical and alternative complement pathway inhibiting the
formation and promoting the catabolism of the C3 (C4b2a,
C3bBb) and C5 complex (C4b2a3b, C3bBb3b) on autologous
cells (Medof et al., 1984; Kinoshita et al., 1985; 1986; Fujita
et al., 1987; Mold et al., 1990). DAF was first isolated from
erythrocyte membranes (Nicholson-Weller et al., 1982) and
was also found on cells with close contact to serum comple-
ment proteins, on leucocytes, monocytes, platelets (Nichol-
son-Weller et al., 1985; Berger & Medof, 1987; Davis et al.,
1988) and endothelial cells (Asch et al., 1986). Recently DAF
was also found in extravascular cells and tissues (Medof et
al., 1987), in the myocard (ZimInermann et al., 1990), in
mesothelial cells, in the epithelium of the urogenital tract
(Quigg et al., 1989) and gastrointestinal tract and fibrillar
structures of the extracellular matrix (Werth et al., 1988;
Sayama et al., 1991). DAF is also expressed on the cell
surface of malignant tumours, in various transformed cell
lines of the myeloid, T and B cell origin (Hadam, 1989) and
in some solid tumour cell lines, in melanomas, breast car-
cinomas (Cheung et al., 1988), renal cell carcinomas (Terachi
et al., 1991) and in HeLa tumour cells (Medof et al., 1987).
DAF-positive tumour cells were found to be more resistant
against complement cytotoxicity in the presence of auto-
logous antibodies on their surfaces than were DAF-negative
tumour cells (Cheung et al., 1988; Terachi et al., 1991). DAF
was therefore suggested as a protecting protein for tumour
cells against complement-mediated cytotoxicity in vivo.
Although the epithelium of the lower gastrointestinal tract
was reported to express DAF (Medof et al., 1987), studies
focussing on the expression of DAF in colorectal carcinomas
are still missing. The present study therefore aims at inves-
tigating the expression of DAF in adenomas and colorectal




Tissues and cells Tissue samples from patients who under-
went tumour resection of the colon or rectum reached our
laboratory within 1 h after removal. Tissue samples were
collected from the cancerous lesion, from the unaffected
mucosa and from adenomas found in the removed tissue.
They were quick frozen in liquid nitrogen and stored at
- 70°C until sectioning. Serial sections of 4 to 6 gm thickness
were cut, extensively air dried, fixed in acetone for 10 min at
room temperature, then stained immediately or stored at
- 20°C for a short time. The collection comprised 20 tissue
samples of unaffected mucosa, 20 adenomas, and 88 car-
cinomas. The tumours, whose primary site and metastatic
spread at the time of operation were well documented, have
been typed, graded, and staged according to the International
Union Against Cancer (UICC) classification (Dukes &
Bussey, 1958; Hermanek & Sobin, 1987; Jass & Sobin, 1987).
Ten carcinomas (11.4%) were grade I, 66 (75.0%) were grade
II, and 12 (13.6%) were grade III; 23 (26.1%) were mucinous
and 65 (73.9%) were nonmucinous adenocarcinomas. Ac-
cording to the Dukes' staging there were 34 stage A patients
(38.6%), 27 stage B patients (30.7%), 26 stage C patients
(29.5%), and one patient with liver metastasis. Twenty-four
(27.3%) carcinomas were located in the right hemicolon, 64
(72.7%) in the left hemicolon. The colon carcinoma cell line
HT29 (ATCC, Rockville, MA) was raised in RPMI 1640
medium (Gibco, Paisley, Scotland, UK) containing 10%
foetal calf serum, sodium pyruvat and L-glutamine. Cells
were detached with 0.25% ethylen-diamine-tetraacetate
(EDTA), centrifuged at 1000 r.p.m. for 5 min, and washed in
RPMI 1640. Cytospins were made, air-dried, fixed in acetone
for 10min, and stained immediately or stored at - 20°C.
Reagents and staining procedure MAb BRIC110 (IgG 1
isotype) and 143-30 (IgGI t isotype) were used for immuno-
histochemical detection of CD55 antigen (Hadam, 1989).
MAb BRIC 110 was kindly provided by D.J. Anstee, Oxford,
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UK, mAb 143-30 by R. Vilella, Barcelona, Spain, on the
occasion of the Non-Lineage/Natural Killer Section Meeting
of the IVth International Workshop and Conference on Leu-
cocyte Differentiation Antigens held in Vienna, February
1989. To underline that we are dealing in our study with
those DAF epitopes recognised by the CD55 monoclonal
antibodies BRIC110 and 143-30, we use the term 'DAF
(CD55)' when presenting and discussing own data while
using the term 'DAF' when we cite other authors using
unclustered mAbs. Monoclonal antibody binding was
detected with a polyclonal biotinylated sheep antibody to
mouse immunoglobulins (Amersham, High Wycomb, UK)
and a streptavidin-biotinylated peroxidase complex (Amer-
sham). 3-Amino-9-ethylcarbazole (AEC) and N'N'-
dimethylformamid (DMF) were obtained from Sigma
Chemical Co. (St Louis, MO). The mAbs were diluted
I:1000 in phosphate-buffered saline (PBS), biotinylated sheep
antibody to mouse immunoglobulin was diluted 1:50 in PBS,
and the streptavidin peroxidase complex was diluted 1:100.
Incubation times were 1 h at room temperature for the
primary antibody and 30 min for the second and third step
reagents. Using AEC as the chromogen (0.4 mg ml-' in
0.01% H202 for 30min), the peroxidase reaction caused an
intense red precipitate. The sections were rinsed in tap water,
counterstained in Harris' hematoxylin and mounted with
glycerol gelatin. Isotype-matched controls with irrelevant
mAb were carried out on a limited number of normal
mucosae and colon carcinomas and revealed no isotype-
associated side reaction in or on epithelial cells. Each frozen-
section series contained a negative control without the
primary reagent; staining was observed solely in granulocytes
whose endogenous peroxidase was not blocked for the benefit
of optimal antigenicity, and to a much lesser extent in some
epithelial areas due to endogeneous biotin.
Evaluation A semiquantitative evaluation system was used
to determine the antigen expression in normal, adenoma, and
carcinoma tissue and cells. Antigen expression was scored
' + ' whenever specific staining was detectable, and '-' when
no antigen was detectable. To evaluate the amount of stained
cells, a semiquantitive scoring system was established:
' + > -' indicates that stained cells clearly outnumbered the
unstained cells; ' + / - ' indicates that positive and negative
cells were found in equal proportions; '- > +' means that
unstained cells outnumbered the stained cells. According to
this system, the antigen expression was correlated with
tumour grade, type, stage and location of the tumour along
the large bowel. The Fisher's exact test was applied for
statistical analysis.
Flow cytometry
For flow cytometry 1 x 106 cells of HT29 were used per
probe. Cells were suspended in FACS-medium containing
RPMI, FCS, NaH3 and HEPES buffer. HEA 125, a mono-
clonal antibody which detects an epithelium-specific glyco-
protein, Egp34, in normal and neoplastic transformed
epithelial cells (Momburg et al., 1987) was used as positive
control. CD53 (HD77), a monoclonal antibody which detects
the leucohistiocytic population and a probe without the
primary antibody were used as negative controls. Cells were
incubated with the CD55 antibody BRIC 110 diluted 1:200,
and after three washing steps with the polyclonal FITC-
coupled goat-anti-mouse antibody (Dianova Hamburg, Ger-
many) diluted 1:50. The incubation time for each antibody
was 1 h. After three washing steps propidium jodide
(1 ;tg ml-' diluted in FACS-medium) was used for gating out
the living cells. Flow cytometry was performed on a FACS-
cang (Becton Dickinson) with the LYSYS II software prog-
ramme.
Results
The expression of DAF(CD55) in normal colonic mucosa, in
adenomas and carcinomas was immunohistochemically stud-
ied with mAb BRIC110. Previous studies found DAF exp-
ressed in the epithelium of the lower gastrointestinal tract
(Medof et al., 1987), we found DAF(CD55) only sporadically
localised in the epithelium of 3/20 normal colonic mucosae
with CD55 BRIC110. In these three cases DAF(CD55) was
expressed in small foci on the luminal surface of the
epithelium in the upper parts of the crypts. A control study
was performed with the mAb 143-30, another CD55
antibody which was also characterised on the IVth Work-
shop on Leucocyte Typing (Hadam, 1989). MAb 143-30 like
BRIC110, revealed that DAF(CD55) was only sporadically
expressed in the normal colonic epithelium (Figure la,b). In
the normal gut wall mAb BRICI 10 detected DAF(CD55) in
fibrillar structures and fibroblasts, particularly in the sub-
mucosa, in nerve fibres, in reticular cells of lymph follicles
and weakly in some endothelial cells; smooth muscle cells of
the gutwall and vessel wall, ganglion cells, B cells of lymph
follicles, T cells and plasma cells were negative. MAb 143-30
showed similar results; in addition, endothelial cells were
somewhat stronger positive and B cells of lymph follicles
were strongly positive. It is not excluded that, in analogy to
other DAF mAbs (Kinoshita et al., 1985), BRICl10 and
143-30 although both reacting with the DAF molecule
(Hadam, 1989) recognise different epitopes.
In colorectal adenomas mAb BRIC 110 showed DAF(CD55)
in the whole epithelium of 5/20 adenomas, 5/20 adenomas
were completely negative. 10/20 adenomas focally showed
et
b
Figure 1 (a) In normal colonic epithelium DAF(CD55) is only
sporadically expressed on the luminal surface of the upper parts
of the crypts. DAF(CD55) lines as a thin band the apical surface
of the epithelium. The dark stained cells are granulocytes whose
endogenous peroxidase was not blocked. The lymphocyte popula-
tion, e.g. T cells and plasma cells, do not express DAF(CD55) .
Staining was done with mAb BRIC 110 ( x 125). (b) As a rule,
colonic epithelium is negative for DAF(CD55). In contrast, there
is strongly positive staining of the fibrillar structures in the
stroma. Staining was done with mAb 143-30 ( x 125).812 K. KORETZ et al.
DAF(CD55) expression, three of which had more positive
cells than negative ones. Two further cases contained positive
and negative tumour cells in about equal proportions and
five others had more negative tumour cells than positive ones
(Table I). DAF(CD55) was essentially localised on the
luminal cell surface (Figure 2a); occasionally, apico-lateral
and baso-lateral cell surfaces were positive, too (Figure 2b,c).
MAb 143-30 showed a similar DAF(CD55) expression in
adenomatous epithelium.
In colorectal carcinomas DAF(CD55) was expressed on
the cell surface of all tumour cells in 5/88 carcinomas; 31/88
were completely negative (Table I). 52/88 showed DAF-
(CD55) expression only focally; 15 had more positive cells
than negative ones, nine showed positive and negative
tumour cells in about equal proportion, and 28 were pro-
minently negative. Representative cases stained with mAb
143-30 showed a staining pattern similar to that of BRIC 110.
However, there was also some reactivity within the cyto-
plasm. The stroma surrounding the tumour nodules strongly
expressed DAF(CD55). The location of DAF(CD55) expres-
sion in colorectal carcinoma was the same as described for
adenomas; most tumours expressed DAF(CD55) on the
apical cell surface (Figure 3c). In the stroma there was strong
expression ofDAF(CD55) in peritumorous fibrillar structures
and fibroblasts (Figure 3b). There was no statistical correla-
tion between presence vs absence of DAF(CD55) and the
tumour grading or staging. However, DAF(CD55) was more
frequently expressed in mucinous carcinomas (P = 0.007,
Fisher's exact test). Finally, there was no statistical correla-
tion between the mode of DAF(CD55) expression and the
tumour location (right versus left hemicolon).
The colon carcinoma cell line HT29 expressed DAF(CD55)
in almost all tumour cells (Figure 4a). DAF(CD55) was in
varying intensities detectable on the cell surface. The cell line
had subpopulations of strongly positive tumour cells with
positive cytoplasm and of faintly positive tumour cells. The
fluorescence histogram revealed that almost all tumour cells
expressed DAF(CD55). The peak of DAF(CD55) was
broader than that of the positive control Egp34 (HEA125), a
broadly expressed but epithelium specific glycoprotein (Mom-
burg et al., 1987), because of the heterogeneous antigen
density of DAF(CD55) on the tumour cell population
(Figure 4b).
fibrillar structures, especially in the submucosa, while
DAF(CD55) was only sporadically detected in the epithelium
of 3/20 colon specimens. In these three cases DAF(CD55)
was expressed in small foci of epithelial cells carrying the
molecule on the luminal cell surface. In a recent study





Although DAF was formerly found only on cells with close
contact to serum proteins, the extensive study of Medof et al.
(1987) showed that DAF is broadly expressed in cells, tissues
and fluids outside the vascular space. We investigated the
expression of DAF(CD55) in 20 normal colonic tissues by an
immunohistochemical technique using the murine mAb
BRIC110 (Spring et al., 1987; Hadam, 1989). BRIC110
recognises a glycoprotein which was formally found on eryth-
rocytes, leucocytes, platelets and several haematopoietic cell
lines. This glycoprotein carries Cromer-related blood group
antigens on normal erythrocytes and is absent or altered on
erythrocytes of patients with the Inab phenotype (Spring et
al., 1987). We observed strong DAF(CD55) reactivity in
Table I Expression ofDAF(CD55) in 20 adenomas and 88 colorectal
carcinomas
Adenomas Carcinomas
Score n = 20 % n = 88 %
+ 5 25.0 5 5.7
+ > - 3 15.0 15 17.1
+ /- 2 10.0 9 10.2
-> + 5 25.0 28 31.8
5 25.0 31 35.2
Notes: 'A>B', cells with staining modality A clearly outnumbered
those with modality B; 'A/B', + and - cells were found in equal
proportions.
Figure 2 (a) Expression of DAF(CD55) in a well-differentiated
adenoma. DAF(CD55) lines as a thin band only the apical cell
surface of the epithelium. The scarce tumour stroma shows
DAF(CD55) positive fibrillar-reticular structures ( x 62.5). (b)
Occasionally DAF(CD55) was found on the apico-lateral and
baso-lateral cell surfaces in addition to the thin-banded apical cell
surface in colon adenomas ( x 125). (c) The adenoma of B is
localised in the neighbourhood of a moderately differentiated
carcinoma. In contrast to the overall expression of DAF(CD55)
on the cell surface of the adenoma, DAF(CD55) was expressed in
small foci on the cell surface of the malignant transformed












Figure 3 (a) Expression of DAF(CD55) in a moderately
differentiated and non-mucinous adenocarcinoma. DAF(CD55)
lines as a thin band the apical surface of the tumour epithelium
and is focally expressed on the apico-lateral cell surface. In the
tumour stroma fibrillar structures and fibroblasts are strongly
positive. Staining was done with mAb BRICI 10 ( x 125). (b) In
this moderately differentiated and non-mucinous adenocarcinoma
DAF(CD55) was not expressed in the tumour epithelium but
strongly in the tumour stroma. Staining was done with mAb
143-30 ( x 125).
epithelium of the lower GI-tract, pooled anti-DAF mAbs
were used. As various epitopes on the DAF molecule have
been defined by different mAbs (Kinoshita et al., 1985), it is
not excluded that the CD55BRICl 10 fails to recognise an
epitope of DAF which is expressed in normal colonic
epithelium and is detected by pooled mAbs. However, a
control staining with CD55(143-30), another mAb directed
against the DAF molecule, showed a reactivity corresponding
to that of BRIC110; the colonic epithelium was likewise
negative. Despite the lack of DAF(CD55) in normal colonic
epithelium, DAF(CD55) was focally expressed in most
adenomas and carcinomas at the luminal cell surface. We
show here that DAF(CD55) tends to be overexpressed in
neoplastic colon epithelia, especially in mucinous carcinoma.
In vitro DAF(CD55) expression appears to be a common
feature of carcinoma cell lines. Apart from HT29, detection
of DAF(CD55) was recently found on CaCo2 and SK-CO15
human intestinal cell lines (Lisanti et al., 1989). DAF was
also found expressed in several other carcinomas, HeLa cells
(Medof et al., 1987) and breast carcinomas (Cheung et al.,
1988). The possible functions of DAF on human tumour
cells have so far been investigated on a very few carcinomas,
namely on renal carcinoma cells and melanomas (Cheung et
al., 1988; Terachi et al., 1991). Membrane deposition of
Figure 4 (a) Expression of DAF(CD55) in HT29 cells, a cyto-
spin stained with mAb BRICI 10. Almost all cells express
DAF(CD55) though in various intensities. Some strongly positive
cells are also positive in the cytoplasm, in other cells DAF(CD55)
is hardly visible ( x 125). (b) Fluorescence histogram of HT29
cells stained with BRICl10. HD77, a mAb directed against
leucohistiocytic cells, is the negative control; HEA125, a mAb
against the epithelial epitope Egp34, the positive control.
DAF(CD55) is expressed on the cell surface of almost all tumour
cells in various intensities.
autologous antibodies against these tumour cells was found
to sensitise them for complement-mediated cytotoxicity. In
these experiments some tumour cells underwent complement-
mediated lysis while others did not. The expression of DAF
on the cell surface was found to be responsible for comple-
ment resistance, and anti-DAF mAb rendered complement-
insensitive cell lines into sensitive ones (Cheung et al., 1988).
Thus, DAF served as a tumour cell protecting protein on
renal cell carcinomas and melanomas. Recent studies sug-
gested the application of anti-DAF Fc-antibodies in conjunc-
tion with autologous tumour cell antibodies as one way of
tumour effective killing (Cheung et al., 1988; Terachi et al.,
1991), although the wide distribution of DAF in various
normal cells and tissues is likely to be a severe restriction
factor for a systemic application of anti-DAF. Nevertheless,
the immunohistochemical determination of DAF expression
in individual tumours can help to select carcinomas which
are susceptible for agents that modify DAF expression or
function (Cheung et al., 1988).
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